国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2010年
2期
103-104
,共2页
华蟾素%内膜癌%存活素%凋亡
華蟾素%內膜癌%存活素%凋亡
화섬소%내막암%존활소%조망
Cinobufagin%Endometrialcarcinoma%Survivin%Apoptosis
目的 探讨华蟾素对体外培养的内膜癌HHUA细胞存活素表达的影响.方法 体外培养内膜癌HHUA细胞,以不同浓度的华蟾素干预后,应用RT-PCR检测存活素的表达,以流式细胞仪检测细胞凋亡.结果 内膜癌HHUA细胞对照组的存活素mRNA表达为(1.22±0.23),细胞凋亡率为(3.11±0.98)%.0.25 mg/ml 华蟾素对内膜癌HHUA细胞存活素mRNA和细胞凋亡率无影响(q=2.89、P>0.05; q=3.12、P>0.05);2.5 mg/ml华蟾素干预后,内膜癌HHUA细胞存活素mRNA表达为(0.73±0.26)、癌细胞凋亡率为(26.50±6.36)%,与对照组比较有统计学意义(q=5.68、P<0.05;q=10.23、P<0.05);但25 mg/ml华蟾豢组与2.5 mg/ml华蟾素组比较,存活素mRNA表达、细胞凋亡率均无统计学意义(q=3.49、P>0.05;q=4.35、P>0.05).结论 2.5 mg/ml华蟾素可抑制内膜癌HHUA细胞存活素mRNA的表达,抑制癌细胞增殖.
目的 探討華蟾素對體外培養的內膜癌HHUA細胞存活素錶達的影響.方法 體外培養內膜癌HHUA細胞,以不同濃度的華蟾素榦預後,應用RT-PCR檢測存活素的錶達,以流式細胞儀檢測細胞凋亡.結果 內膜癌HHUA細胞對照組的存活素mRNA錶達為(1.22±0.23),細胞凋亡率為(3.11±0.98)%.0.25 mg/ml 華蟾素對內膜癌HHUA細胞存活素mRNA和細胞凋亡率無影響(q=2.89、P>0.05; q=3.12、P>0.05);2.5 mg/ml華蟾素榦預後,內膜癌HHUA細胞存活素mRNA錶達為(0.73±0.26)、癌細胞凋亡率為(26.50±6.36)%,與對照組比較有統計學意義(q=5.68、P<0.05;q=10.23、P<0.05);但25 mg/ml華蟾豢組與2.5 mg/ml華蟾素組比較,存活素mRNA錶達、細胞凋亡率均無統計學意義(q=3.49、P>0.05;q=4.35、P>0.05).結論 2.5 mg/ml華蟾素可抑製內膜癌HHUA細胞存活素mRNA的錶達,抑製癌細胞增殖.
목적 탐토화섬소대체외배양적내막암HHUA세포존활소표체적영향.방법 체외배양내막암HHUA세포,이불동농도적화섬소간예후,응용RT-PCR검측존활소적표체,이류식세포의검측세포조망.결과 내막암HHUA세포대조조적존활소mRNA표체위(1.22±0.23),세포조망솔위(3.11±0.98)%.0.25 mg/ml 화섬소대내막암HHUA세포존활소mRNA화세포조망솔무영향(q=2.89、P>0.05; q=3.12、P>0.05);2.5 mg/ml화섬소간예후,내막암HHUA세포존활소mRNA표체위(0.73±0.26)、암세포조망솔위(26.50±6.36)%,여대조조비교유통계학의의(q=5.68、P<0.05;q=10.23、P<0.05);단25 mg/ml화섬환조여2.5 mg/ml화섬소조비교,존활소mRNA표체、세포조망솔균무통계학의의(q=3.49、P>0.05;q=4.35、P>0.05).결론 2.5 mg/ml화섬소가억제내막암HHUA세포존활소mRNA적표체,억제암세포증식.
Objective To investigate the effect and significance of cinobufagin on the expression of survivin of HHUA cells in the endometrial carcinoma cultured in vitro. Methods HHUA cells of endometrial carcinoma were cultured in vitro. After being intervened by cinobufagin with different concentration, the expression of survivin was measured by RT-PCR and the cellular apoptosis was tested by flow cytometry. Results In the control group: mRNA expression of survivin of HHUA cells in endometrial carcinoma was (1.22±0.23), cellular apoptutic rate was (2.31± 0.98)%; cinobufagin of 0.25 mg/ml didn't affect the survivin and cellular apoptotic rate (q=2.89, P>0.05: q=3.12, P>0.05) ; after being exposed to einobufagin of 2.5 mg/ml, the expression of survivin was (0.73± 0.26), and cellular apoptotic rate was (26.50± 6.36) %, with all of these data being different from the control group significantly (q=5.68, P<0.05; q= 10.23, P<0.05) ; the actions of cinobufagin of 25 mg/ml on mRNA expression of survivin and apoptotic rate were similar to cinobufagin of 2.5 mg/ml (q=3.49, P>0.05; q=4.35, P>0.05) . Conclusion Cinobufagin of 2.5 mg/ml inhibit the mRNA expression of survivin and proliferation of HHUA cells in endometrial carcinoma.
